Vitamin D is among the most-supplemented compounds in the world, and among the most confusing to evaluate — observational studies show strong mortality associations that randomized trials have largely failed to replicate on all-cause mortality, while showing a real, smaller signal on cancer death.
Low vitamin D status is one of the most consistent observational predictors of mortality in the literature. It is also one of the clearest cautionary tales in longevity medicine about confusing correlation with causation.
People with low vitamin D levels are disproportionately older, sicker, more obese, less physically active, and spend less time outdoors — all independent mortality risk factors. Low vitamin D may partly be a marker of poor health rather than a cause of it, a pattern epidemiologists call reverse causation. This is exactly the kind of question a randomized trial is designed to resolve, and one large trial has done more to resolve it than any other.
VITAL (Vitamin D and Omega-3 Trial), published in the New England Journal of Medicine in 2018–2019, randomized nearly 26,000 U.S. adults to vitamin D3 (2000 IU/day), omega-3 fatty acids, both, or placebo, and followed them for a median of 5.3 years. On the primary endpoints, vitamin D supplementation did not significantly reduce the composite of major cardiovascular events or invasive cancer, and did not significantly reduce all-cause mortality.
A secondary analysis did find a reduction in cancer death specifically, more pronounced with longer follow-up and in participants who were not overweight or obese — a signal that has since been supported by pooled meta-analyses of multiple vitamin D RCTs, which converge on roughly a 10–13% relative reduction in cancer mortality despite no clear effect on cancer incidence or all-cause mortality.
A frequently raised critique of VITAL and similar trials is that they enrolled a general population largely replete in vitamin D, diluting any effect that might exist specifically in deficient individuals. Some subgroup and cohort analyses support this — effects on falls, fractures, and infection risk tend to be more consistent in people with baseline levels below roughly 20 ng/mL. Geroevidence's current read is that this hypothesis is plausible and consistent with the data pattern, but has not itself been confirmed in a dedicated deficient-only RCT powered for mortality.
The best available randomized evidence does not support vitamin D supplementation as a general-population all-cause mortality intervention, despite a real and consistent effect on cancer mortality specifically. Correcting frank deficiency remains standard, well-supported practice for its established indications (bone health, established deficiency); using it as a broad longevity intervention in vitamin D-replete adults is not supported by the largest trial to date.
This information is provided for educational reference only and does not constitute medical advice or a treatment recommendation.